Amount (US$M)



Total: $155.5M (Year-to-date: $906.45M)

Agenus Inc. (Lexington, Mass.)

Merck & Co. Inc. (Kenilworth, N.J.)


For the advancement of an undisclosed antibody under the license and research collaboration agreement with Merck


Aicuris Anti-infective Cures GmbH

Merck & Co. Inc. (Kenilworth, N.J.)


€105M (US$122M) on the FDA approval of letermovir for preventing cytomegalovirus (CMV) reactivation in seropositive adults undergoing allogeneic hematopoietic stem cell transplant (HSCT). There could be cause for a double celebration shortly, as the drug is also up for decision at the EMA's Committee for Human Medicinal Products (CHMP).


Argos Therapeutics Inc. (Durham, N.C.)

Lummy (Hong Kong) Co. Ltd.


For the successful initiation of technology transfer for the manufacturing of rocapuldencel-T to Lummy; the product is Argos' most advanced candidate, which is being evaluated in the pivotal ADAPT phase III trial for the treatment of metastatic renal cell carcinoma.


Genmab A/S (Copenhagen)

Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.)


For Janssen Biotech Inc. selling $1B worth of Darzalex (daratumumab) in a calendar year; Janssen licensed the multiple myeloma drug in 2012


Genmab A/S (Copenhagen)

Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.)


For Janssen submitting a type II variation application to the EMA seeking to broaden the existing marketing authorization for Darzalex (daratumumab) to include use in combination with bortezomib, melphalan and prednisone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant


Jubilant Biosys Ltd. (Bangaluru; a subsidiaary of Jubilant Life Sciences Ltd.)

Sanofi SA (Paris)


For the successful transition of a collaborative program to the next phase in the discovery and development process; the companies inked an alliance in 2016 focused on small-molecule inhibitors for multiple targets in diabetes and obesity


Lead Pharma Holding BV (Nijmegen, the Netherlands)

Sanofi SA (Paris)


Achieved a third milestone under its 2015 research collaboration with Sanofi to develop small molecules directed against the nuclear hormone receptor ROR gamma



Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.


No Comments